| Nov 7 |
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
|
| Oct 24 |
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
|
| Oct 15 |
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy
|
| Sep 5 |
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders
|
| Aug 8 |
Why Digital Turbine Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
|
| Jun 20 |
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
|
| May 30 |
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
|
